What monitoring is recommended after initiating PCSK9 inhibitors?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Monitoring after starting PCSK9 inhibitors focuses on confirming the LDL-C reduction and ensuring the patient can tolerate the therapy. Begin with a baseline lipid panel, then recheck lipids after about 4 to 12 weeks to assess how much LDL-C has fallen and to gauge adherence. Continue periodic lipid testing over time to verify ongoing LDL-C lowering and to guide any dose adjustments or addition of other therapies. Watch for injection-site reactions as part of tolerability monitoring. Routine CK or liver enzyme testing isn’t required solely because of PCSK9 inhibitors, since these drugs have a favorable hepatic and muscle safety profile, unless there are symptoms or other risk factors prompting testing. Therefore, the recommended approach is baseline lipid panel plus periodic lipid checks, with attention to injection-site reactions and no routine CK/LFT testing.